Format

Send to

Choose Destination
Expert Rev Vaccines. 2012 Nov;11(11):1293-303. doi: 10.1586/erv.12.108. Epub 2012 Nov 14.

Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.

Author information

1
MedImmune, LLC, Gaithersburg, MD, USA.

Abstract

Influenza B is responsible for significant morbidity in children and adults worldwide. For more than 25 years, two antigenically distinct lineages of influenza B viruses, B/Yamagata and B/Victoria, have cocirculated globally. Current influenza vaccine formulations are trivalent and contain two influenza subtype A strains (A/H1N1 and A/H3N2) but only one B strain. In a half of recent influenza seasons, the predominant circulating influenza B lineage was different from that contained in trivalent influenza vaccines. A quadrivalent live-attenuated influenza vaccine (Q/LAIV) that contains two B strains, one from each lineage, has been developed to help provide broad protection against influenza B. Q/LAIV was recently approved for use in the USA in eligible individuals 2-49 years of age. This review summarizes clinical trial data in support of Q/LAIV.

PMID:
23151111
DOI:
10.1586/erv.12.108
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center